NCT06080841Recruiting
Curcumin Supplementation in Cervical Cancer
Evaluation of Curcumin Supplementation on p53 Levels and Apoptosis in Tumor Cells From Patients With Locally Advanced Cervical Cancer
Source: ClinicalTrials.gov · Last updated 25 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation? Participants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation: 1. 1 g of curcumin 2. 1 g of curcumin + piperine 3. 3 g of curcumin 4. 3 g of curcumin + piperine 5. 6 g of curcumin 6. 6 g of curcumin + piperine
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 19 Sept 2023
- Start date
- 19 Apr 2023
- Primary completion date
- Dec 2025
- Lead sponsor
- National Institute of Cancerología
- Diseases
- Cervical cancer
- NCT number
- NCT06080841
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 19 Apr 2023 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving concomitant treatment with an experimental drug.
- Patients with previous or concomitant malignancy except non-melanoma skin carcinoma.
Other illness
- Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.
- Patients with vesicovaginal or vesicorectal fistula are diagnosed.
Other
- Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.
Who the study is looking for
- Understanding the nature of the study and giving a written consent report.
- Women \> 18 years old.
- ECOG performance status: 0-2.
- Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
- Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.
- Classified with clinical stage IB3-IVA (FIGO 2018).
- Candidates to receive concomitant QT-RT followed by BT.
- With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria.
- Patients without prior treatment based on QT-RT.
- Hemoglobin ≥ 10 g/dL.
- Leukocytes ≥ 4000/mm3.
- Platelets ≥ 100,000/mm3.
- Adequate liver function.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Cancerologia Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.